May 05, 2026 —
A recent study published in Gene Therapy reported a significant clinical response following systemic administration of adeno-associated virus gene therapy in a large animal model of late-stage lysosomal storage disease. Lysosomal storage diseases are inherited metabolic disorders caused by deficiencies in lysosomal enzymes, leading to the accumulation of undegraded substrates, progressive tissue dysfunction, severe clinical symptoms, and early mortality in many cases. While many gene therapy studies focus on early-stage or pre-symptomatic disease, this study is notable for evaluating therapeutic benefit in advanced disease, a stage where treatment options are often limited.
The researchers used systemic AAV delivery to enable broad tissue distribution and target multiple affected organs simultaneously. According to the reported findings, treatment led to improved clinical symptoms, restored enzyme activity in key organs, and reduced pathological substrate accumulation. Improvements were observed in both visceral and neurological manifestations, suggesting that optimized AAV vector design and systemic delivery may help address the multi-organ nature of lysosomal storage diseases.
The study also highlighted several translational considerations, including durable therapeutic transgene expression, a favorable safety profile during the monitoring period, and limited immune-mediated adverse events. The vector strategy incorporated capsid and promoter engineering to enhance tissue tropism and transgene expression, with additional attention to dose optimization, biodistribution, and manufacturing scalability. While the authors emphasized the need for longer-term studies to confirm durability and monitor late-onset safety risks, the findings support the potential of systemic AAV gene therapy as a promising approach for advanced lysosomal storage diseases.
